WASHINGTON (AP) ? Republican vice presidential candidate Paul Ryan says he and Mitt Romney will wait until after they're elected to disclose what tax loopholes they plan to get rid of.
Ryan tells Fox News that ? quote ? "that is something that we think we should do in the light of day, through Congress."
Ryan says the GOP ticket wants to get feedback from Americans about what tax cuts should be kept and what loopholes to close.
In the interview, Ryan accused President Barack Obama of cutting Medicare to pay for his federal health care overhaul. It was the Romney campaign's line of the day, and it drew a blistering response from Obama's campaign, which labeled the latest Romney ad dishonest and hypocritical.
A NASA spacecraft in orbit around Mars snapped a new, incredibly crisp color photo of the Curiosity rover on the surface of the Red Planet.
The photo was taken by the High Resolution Imaging Science Experiment (HiRISE) camera on NASA's Mars Reconnaissance Orbiter, which has been circling the Red Planet since 2006. The new image shows Curiosity at its Gale Crater landing site, with the effects of its rocket-powered descent to the surface clearly visible.
"The rover appears as double bright spot plus shadows from this perspective, looking at its shadowed side, set in the middle of the blast pattern from the descent stage," Alfred McEwen, HiRISE principal investigator at the University of Arizona in Tucson, said in a statement. "This image was acquired from an angle looking 30 degrees westward of straight down. We plan to get one in a few days looking more directly down, showing the rover in more detail and completing a stereo pair."
The photo also reveals spectacular details of the layered bedrock at Gale Crater, NASA officials said. As part of its mission, Curiosity will examine the crater's layers of rock and soil to determine whether Mars has an environment that is, or ever was, suitable for microbial life.
Engineers at NASA's Jet Propulsion Laboratory (JPL) in Pasadena, Calif. recently upgraded Curiosity's computers and software to prepare the rover for driving and using the tools on its robotic arm. Mission operators affectionately called this four-day procedure a "brain transplant," since it involved transitioning Curiosity from landing to now operating on the Martian surface. [Gallery: Curiosity's 1st Photos of Mars]
"We have successfully completed the brain transplant," Mike Watkins, Curiosity's mission manager at JPL, said in a statement. "Now we are moving on to a new phase of functional checkouts of the science instruments and preparations for a short test drive."
Curiosity is expected to take its first drive within roughly a week. The rover's first outing will likely include short motions forward and in reverse, and a turn, NASA officials said. Mission controllers will prepare and test each of the wheels' drive and steering motors before Curiosity is moved for the first time.
"It's fair to say that the scientists, not to mention the rover drivers, are itching to move," said Ashwin Vasavada, deputy project scientist for the Curiosity mission at JPL.
Curiosity, which is also known as the Mars Science Laboratory, touched down on Mars on the night of Aug. 5 (PDT; Aug. 6 EDT). NASA's Mars Reconnaissance Orbiter captured photos of the rover on its parachute as it descended to the Martian surface, and also observed the robotic explorer at Gale Crater one day after landing.
Scientists have been combing through photos taken by HiRISE and Curiosity's own cameras to narrow down potential areas for the rover to drive to and investigate in the future. Ultimately, Curiosity will explore a mysterious mountain, called Mount Sharp, which rises up three miles (4.8 kilometers) from roughly the center of Gale Crater.
"The science and operations teams are evaluating several potential routes that would take us to Mount Sharp, with perhaps a few waypoints to inspect some of the different terrains we've identified as we map the landing area," Vasavada said. "As we have reported many times before, it's going to take us a good part of our first year to make it to the layered sediments on Mount Sharp."
The $2.5 billion Curiosity rover will spend two years on the Red Planet investigating the Martian terrain. The 1-ton rover is NASA's most ambitious planetary science mission attempted to date.
Visit?SPACE.com?for?complete coverage of NASA's Mars rover Curiosity. Follow SPACE.com on Twitter @Spacedotcom. We're also on Facebook and?Google+.
Copyright 2012 SPACE.com, a TechMediaNetwork company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
We?re constantly hearing about the new resurgence of people who love to run. Marathons, triathlons, or just leisurely jogs around the neighborhood park have all come back to the forefront of exercising. And why not? It?s a great, total body workout that you can do for free anywhere with the added bonus of raising money or awareness for some great causes. The problem is, where to begin? You may already know you love running, but you need to train for an upcoming event. Or you may have never given running a chance and you want to know how to start. Health and Fitness brings you the answer to these questions and many others with the Women?s Guide to Running on iPad and Android.
This digital magazine has it all; expert advice, motivation, training plans, advice for preventing running related injuries, gym workouts that will help with your running, race and event coverage, even recipes and nutrition plans to fuel your body so it can perform at its best. From beginner to expert, the Women?s Guide to Running is sure to improve your running and your attitude towards running. Start planning for that 5k today! We promise, with the help of this inspirational guide you?ll achieve your goals in no time flat.
Want more? How about these similar digital magazines....
This entry was posted in iPad Magazines and tagged fitness, health, running, womens. Bookmark the permalink.
I know that the Airbus A380 is a titan, a winged colossus, the biggest passenger airliner in the world and all that. But this pictured taken at LAX—showing an Air France A380 taxiing by a Boeing 737-900—really shows its flabbergasting dimensions. More »
Maybach Music Group Presents Self Made, Vol. 2 Various Artists 2012
About the Author: Buzzbin Mike
I'm the guy behind Buzzbin Magazine. Back in 2008 I put out my first issue of Buzzbin hoping to promote the local music scene in Akron/Canton. Since then we've grown to be the largest alternative press in the area. If you've met any of our crew then you know that we a bunch of hard workers with a passion to represent the community. Who says Akron/Canton/Cleveland is a miserable place to live? Not us. We have one of the best art scenes around, some of the hardest working musicians on the planet, and really great people to fill in everywhere else. We put out a new issue on THE FIRST WEDNESDAY OF EVERY MONTH covering the best art and entertainment found in northeast Ohio. We never miss a beat. Wonder why our mag is choked full of advertisers? Because we know what we're doing. We offer full scale marketing for each and every business that comes to us. We develop marketing campaigns from the ground up, or we'll take over where someone left off. We have the ability to tell everyone about you. And we're open for business. We're not pushy, we're helpful. - Mike (330) 236-5005
Antisense approach promising for treatment of parasitic infectionsPublic release date: 13-Aug-2012 [ | E-mail | Share ]
Contact: John Easton john.easton@uchospitals.edu 773-795-5225 University of Chicago Medical Center
A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.
This precisely focused therapy combines short strands of "antisense" nucleic acid-like material with a small peptide that can transport those strands through cell membranes and into parasites, where they disrupt genetic signals. A similar approach from a team at Yale, published in April, showed comparable promise as a treatment for the parasites that cause malaria.
"This was proof of concept," said study author Rima McLeod, MD, a toxoplasmosis expert and professor at the University of Chicago Medicine. "We were able to cross multiple membranes, to insert the antisense strands into parasites living within cells and prevent them from making several different proteins. We now think we can shut down any of this parasite's genes."
"This approach may even have a role in non-parasitic diseases," she added. It is currently being tested in drug-eluting stents, as a treatment for bacterial or viral infections, including Ebola, and in patients with Duchenne muscular dystrophy, where it can block production of the defective segment of a dysfunctional gene.
The parasite McLeod and colleagues focused on, Toxoplasma gondii, is "probably the most common parasitic infection in the world," she said. "It infects as many as one-third of all humans, about two billion people worldwide." T. gondii causes disease in those who have immature immune systems, particularly those infected in utero. It also can be devastating for those who are immune-compromised and when it causes eye disease.
"New medications are urgently needed," she said. The standard treatments can cause side effects and patients may become hypersensitive to them. There are no medicines that can eliminate certain latent stages of the parasite's life cycle. There is no vaccine for humans.
The new treatment consists of a phosphorodiamidate morpholine oligomer (PMO), a short DNA-like molecule that binds to messenger RNA, preventing it from being translated into protein. This is conjugated to a "transductive peptide," a small molecule that can ferry the PMO across cellular barriers. The combination is known as a PPMO. An earlier study from the McLeod lab showed that such transductive peptides could bring small molecules into the untreatable dormant phase of the parasite.
The researchers tested this system in infected cells in tissue culture and in live, recently infected mice. It was able to knock down production of several distinct proteins.
They first tested their PPMO against easily detectable biomarkers by inserting genes for yellow fluorescent protein and for luciferase, a protein responsible for fireflies' glow, into parasites. Then they exposed parasite-infested cells to low levels of a PPMO targeting one piece of those genes. This reduced yellow fluorescence or dimmed bioluminescence by 40 to 60 percent.
Next, they tested its ability to block production of an enzyme, dihydrofolate reductase (DHFR), that the parasite needs to make folate and to replicate. After 48 hours, DHFR production of intracellular parasites was markedly reduced. Antisense oligomers targeting another enzyme and factors that direct the activity of many genes, called "transcription factors," associated with parasite replication, "also were successful," the authors note, "reducing parasite replication."
When they tested the anti-DHFR PPMO in newly infected mice, the results were dramatic. Within 96 hours, treatment reduced the number of parasites by 83 percent to 97 percent, depending on the measurement technique.
This approach is "paradigm shifting," McLeod said. "It has the potential to abrogate any molecular target and underscores the variety of diseases for which such an approach might apply."
The technology still has a few problems, she said. These PPMOs have a narrow therapeutic index; they can be toxic at a little more than the lowest effective dose. And we have not yet developed a way to eradicate latent stages of T. gondii, which can lie dormant in retina or brain cells for years, but such studies are underway. The researchers hope to use this technique to awaken dormant parasites, and then use drugs or PPMOs that target replicating parasites to kill them or eliminate both active and dormant parasite stages by targeting their plant-like transcription factors and other proteins unique to the parasites that humans don't have.
Much of the credit for developing and testing this system should go to the study's lead author, McLeod said.
Bo-Shiun Lai, a 20-year-old rising fourth-year college student at the University of Chicago, stumbled into his research position in McLeod's laboratory but adapted quickly. "Although it was difficult at the outset," he said, "everyone in the lab helped me develop the project and hone my laboratory techniques along the way."
It paid off. He completed his senior thesis as a junior, with honors, and will be applying for PhD programs.
###
This study was funded by the National Institutes of Health and gifts from the Mann and Cornwell, Taub, Rooney-Alden, Engel, Pritzker, Harris, Zucker, Morel and Mussilami families. Additional authors include Kamal El Bissati, Ying Zhou, Ernest Mui and Alina Fomovska of the University of Chicago, and William Witola, now at Tuskeegee University in Alabama.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Antisense approach promising for treatment of parasitic infectionsPublic release date: 13-Aug-2012 [ | E-mail | Share ]
Contact: John Easton john.easton@uchospitals.edu 773-795-5225 University of Chicago Medical Center
A targeted approach to treating toxoplasmosis, a parasitic disease, shows early promise in test-tube and animal studies, where it prevented the parasites from making selected proteins. When tested in newly infected mice, it reduced the number of viable parasites by more than 90 percent, researchers from the University of Chicago Medicine report in the Proceedings of the National Academy of Sciences.
This precisely focused therapy combines short strands of "antisense" nucleic acid-like material with a small peptide that can transport those strands through cell membranes and into parasites, where they disrupt genetic signals. A similar approach from a team at Yale, published in April, showed comparable promise as a treatment for the parasites that cause malaria.
"This was proof of concept," said study author Rima McLeod, MD, a toxoplasmosis expert and professor at the University of Chicago Medicine. "We were able to cross multiple membranes, to insert the antisense strands into parasites living within cells and prevent them from making several different proteins. We now think we can shut down any of this parasite's genes."
"This approach may even have a role in non-parasitic diseases," she added. It is currently being tested in drug-eluting stents, as a treatment for bacterial or viral infections, including Ebola, and in patients with Duchenne muscular dystrophy, where it can block production of the defective segment of a dysfunctional gene.
The parasite McLeod and colleagues focused on, Toxoplasma gondii, is "probably the most common parasitic infection in the world," she said. "It infects as many as one-third of all humans, about two billion people worldwide." T. gondii causes disease in those who have immature immune systems, particularly those infected in utero. It also can be devastating for those who are immune-compromised and when it causes eye disease.
"New medications are urgently needed," she said. The standard treatments can cause side effects and patients may become hypersensitive to them. There are no medicines that can eliminate certain latent stages of the parasite's life cycle. There is no vaccine for humans.
The new treatment consists of a phosphorodiamidate morpholine oligomer (PMO), a short DNA-like molecule that binds to messenger RNA, preventing it from being translated into protein. This is conjugated to a "transductive peptide," a small molecule that can ferry the PMO across cellular barriers. The combination is known as a PPMO. An earlier study from the McLeod lab showed that such transductive peptides could bring small molecules into the untreatable dormant phase of the parasite.
The researchers tested this system in infected cells in tissue culture and in live, recently infected mice. It was able to knock down production of several distinct proteins.
They first tested their PPMO against easily detectable biomarkers by inserting genes for yellow fluorescent protein and for luciferase, a protein responsible for fireflies' glow, into parasites. Then they exposed parasite-infested cells to low levels of a PPMO targeting one piece of those genes. This reduced yellow fluorescence or dimmed bioluminescence by 40 to 60 percent.
Next, they tested its ability to block production of an enzyme, dihydrofolate reductase (DHFR), that the parasite needs to make folate and to replicate. After 48 hours, DHFR production of intracellular parasites was markedly reduced. Antisense oligomers targeting another enzyme and factors that direct the activity of many genes, called "transcription factors," associated with parasite replication, "also were successful," the authors note, "reducing parasite replication."
When they tested the anti-DHFR PPMO in newly infected mice, the results were dramatic. Within 96 hours, treatment reduced the number of parasites by 83 percent to 97 percent, depending on the measurement technique.
This approach is "paradigm shifting," McLeod said. "It has the potential to abrogate any molecular target and underscores the variety of diseases for which such an approach might apply."
The technology still has a few problems, she said. These PPMOs have a narrow therapeutic index; they can be toxic at a little more than the lowest effective dose. And we have not yet developed a way to eradicate latent stages of T. gondii, which can lie dormant in retina or brain cells for years, but such studies are underway. The researchers hope to use this technique to awaken dormant parasites, and then use drugs or PPMOs that target replicating parasites to kill them or eliminate both active and dormant parasite stages by targeting their plant-like transcription factors and other proteins unique to the parasites that humans don't have.
Much of the credit for developing and testing this system should go to the study's lead author, McLeod said.
Bo-Shiun Lai, a 20-year-old rising fourth-year college student at the University of Chicago, stumbled into his research position in McLeod's laboratory but adapted quickly. "Although it was difficult at the outset," he said, "everyone in the lab helped me develop the project and hone my laboratory techniques along the way."
It paid off. He completed his senior thesis as a junior, with honors, and will be applying for PhD programs.
###
This study was funded by the National Institutes of Health and gifts from the Mann and Cornwell, Taub, Rooney-Alden, Engel, Pritzker, Harris, Zucker, Morel and Mussilami families. Additional authors include Kamal El Bissati, Ying Zhou, Ernest Mui and Alina Fomovska of the University of Chicago, and William Witola, now at Tuskeegee University in Alabama.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Portable air conditioners are small sized and are extremely convenient as they can be easily moved from one room into the other. Portable models however have other advantages as well.
It is quite difficult to live in the absence of constant air conditioning, but this comes with a certain price. A portable air conditioner is a viable solution, as it is easy to move it between rooms or sites. Thus, it is a great cooling solution for homes or offices.
Portable air conditioners can be easily installed and can be moved from one place or room into the other. Compared to the window air conditioners these portable ones are more convenient.
A portable air conditioner is also a great money saving solution, as you only need to purchase one single unit, which can be easily placed wherever you need it. Some of the models weight as less as 36 pounds and are mounted on castors. Compared to the conventional air conditioning system, the portable models have low energy consumption as they cool only one room and not the entire house.
The portable air conditioners offer excellent energy efficiency. The efficiency ranges in average between 8 and 10, but it can also be as high as 15, meaning a 50 percent higher efficiency compared to older air conditioners. As portable air conditioners are small sized, they can be easily fitted against the wall or simply in a corner. Its size is comparable to a room dehumidifier and it actually functions like a dehumidifier.
The humidity of the room is reduced as a smaller model eliminates about 35 pints of moisture on a daily basis from the air of the room. They function based on the heat-exchange principle of the conventional air conditioning systems to cool the air. The air is cooled and dehumidified as the air is circulated through cold evaporator coils. The room air is eliminated through the hot condenser.
In our modern days, most portable air conditioner models include electronic controls allowing you to set the wanted room temperature, operation mode (heat, dehumidify or cool) and blower speed. Hand-held remote controls are also included with the portable air conditioners, enabling you to easily modify the settings with no effort whatsoever.
Portable air conditioners can also include various other features, such as an incorporated air cleaner. Optionally, you can select charcoal air cleaner filter and oscillating louvers, which enables you to distribute the cooled air within the room. The louvers can be switched off allowing the air to flow straight towards you, according to your individual needs.
This article has been viewed 6 time(s).
It is a violation of our terms and conditions for writers to submit material which they did not write and claim it as their own.
If this article infringes on your copyrights, you MUST either call us at 706-866-2295 or send proof of infringement
along with the offending article's title, URL, and writer name to
IdeaMarketers.com
Attn: Marnie Pehrson - Copyright Concern
514 Old Hickory Ln
Ringgold GA 30736 USA
If you email us or use our problem submission form, we CANNOT guarantee we'll receive your notice!
We?re constantly hearing about the new resurgence of people who love to run. Marathons, triathlons, or just leisurely jogs around the
neighborhood park have all come back to the forefront of exercising. And why not? It?s a great, total body workout that you can do for free anywhere with the added bonus of raising money or awareness for some great causes. The problem is, where to begin? You may already know you love running, but you need to train for an upcoming event. Or you may have never given running a chance and you want to know how to start. Health and Fitness brings you the answer to these questions and many others with the Women?s Guide to Running on iPad and Android.
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 13-Aug-2012
Share ]